Aquestive Therapeutics, Inc.(AQST)Earnings, Financials & Key RatiosAquestive Therapeutics, Inc. (AQST) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's persistent net losses, evidenced by a -55.8% net margin in 2026Q1, combined with a negative equity position of -$34.1 million, suggest that the firm faces substantial liquidity risks before achieving a self-sustaining commercial model.
Aquestive Therapeutics, Inc. (AQST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Aquestive Therapeutics, Inc. (AQST) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.07vs $0.14+50.0% | $14Mvs $11M+32.6% |
| Q2 2026 | Mar 4, 2026 | $0.26vs $0.13-100.0% | $13Mvs $13M-2.0% |
| Q4 2025 | Nov 5, 2025 | $0.14vs $0.11-27.3% | $13Mvs $13M-1.1% |
| Q3 2025 | Aug 11, 2025 | $0.14vs $0.18+22.2% | $10Mvs $12M-18.0% |
Recent stock market news and headlines for Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Key metrics vs top competitors for Aquestive Therapeutics, Inc. (AQST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.33 | $430M | -5.70 | -22.61% | -188.09% | — | — | |
| $2.05 | $29.77M | -1.71 | 10429.36% | -1038.77% | — | — | |
| $2.25 | $18.22M | -1.04 | 1.84% | -60.17% | -148.91% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $81.23 | $7.22B | -101.54 | 1031.18% | 7.74% | 46.82% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — |
Aquestive Therapeutics, Inc. (AQST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Aquestive Therapeutics, Inc. (AQST) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Mar 30, 2026·SEC
Mar 20, 2026·SEC
Get notified when AQST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aquestive Therapeutics, Inc. (AQST) stock FAQ — growth, dividends, profitability & financials explained
Aquestive Therapeutics, Inc. (AQST) reported $50.3M in revenue for fiscal year 2025. This represents a 3% decrease from $51.8M in 2016.
Aquestive Therapeutics, Inc. (AQST) saw revenue decline by 22.6% over the past year.
Aquestive Therapeutics, Inc. (AQST) reported a net loss of $68.9M for fiscal year 2025.
Aquestive Therapeutics, Inc. (AQST) had negative free cash flow of $44.3M in fiscal year 2025, likely due to heavy capital investments.
